Back

Incidence of restenosis after drug-coated balloon percutaneous coronary intervention in patients with diabetes mellitus - a single-centre experience

26 August 2023 (12:15 - 12:50)
Organised by: Logo
Congress Presentation Part of: Drug-coated balloons, stents, and scaffolds Restenosis ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Doctor Antonio Hanzek

University Hospital Centre Zagreb, Zagreb (Croatia)

5 More presentations in this session

Presentation thumbnail
Long term safety of paclitaxel coated balloon for de novo non-small coronary lesions
Doctor X. He (Galway, IE)
Abstract Slides
Presentation thumbnail
Two-year outcomes of drug-coated balloon only strategy for de novo lesions in large coronary vessels
Doctor R. Bando (Tokushima, JP)
Abstract Slides Video
Presentation thumbnail
Cost effectiveness analysis of drug coated balloon only angioplasty for de novo coronary artery disease intervention.
Doctor V. Tsampasian (Norwich, GB)
Abstract Slides Video
Presentation thumbnail
Drug coated balloon treatment with or without long inflation time in patients undergoing percutaneous coronary intervention: a propensity score matching analysis
Doctor Y. Fujiwara (Tenri, JP)
Abstract Slides Video
Presentation thumbnail
The impact of underlying plaque characteristics following the novel resorbable magnesium scaffold implantation: an intravascular OCT assessment up to 12-months
Doctor A. Aytekin (Munich, DE)
Abstract Slides Video

Access the full session

Session thumbnail
Drug-coated balloons, stents, and scaffolds

The Event

Event poster

ESC Congress 2023

26 August 2023 12:15 CET
You may be interested in
thumbnail
Congress Session
Strategies and outcomes in in-stent restenosis
thumbnail
Congress Presentation
Usage patterns and outcomes of drug coated ballons at a tertiary care center - a cohort analysis in 462 patients
thumbnail
Congress Presentation
Restenosis patterns after percutaneous coronary intervention with drug-coated balloon for de novo coronary lesions as assessed by optical coherence tomography

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources